Lv4
460 积分 2023-12-26 加入
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
1天前
待确认
A glucocorticoid–FAS axis controls immune evasion during metastatic seeding
1个月前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
1个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
1个月前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
1个月前
已关闭
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
1个月前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
1个月前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
1个月前
已完结
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study
1个月前
已完结
[Guideline for HER2 testing in breast cancer (2024 version)]
2个月前
已完结
皖公网安备34019202002308
